Radioactive iodine

Phase 3Small molecule

UUniversity of Helsinki

Radioactive iodine is one of 5 small molecule programs targeting Thyroid Nodule. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Thyroid NoduleActive, not recruiting

Thyroid NodulePhase 3

Active, not recruiting

Competition

Competitive Landscape

9 competitors in Thyroid Nodule

#DrugCompanyPhaseTrials

Ethanol

Roche

Phase 1

1 2

Radioactive iodine

UUniversity of Helsinki

Phase 3

1 3

Alcohol

Astellas

Phase 1

—4

Synthroid

IInstitut Jerome Lejeune

Preclinical

—5

Amoxil

GGlobal Antibiotics Research and Development Partnership

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Thyroid1 trial

The Dose of Radioactive Iodine Needed to Ablate the Thyroid Remnant Left Behind After Thyroidectomy

Unknown status·UUniversity of Helsinki·Phase 3·NCT00115895·160 enrolled

Thyroid Nodule1 trial

Radiofrequency Ablation Versus I-131 for Solitary Autonomous Thyroid Nodules

Terminated·RRijnstate Hospital·Phase 3·NCT05142904·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Radioactive iodine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Radioactive iodine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Radioactive iodine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Helsinki company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity of Helsinki

Radioactive iodine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Thyroid1 trial

Thyroid Nodule1 trial

References

Drug Info

Quick Facts

Related News